作者
Venkat Koushik Pulla, Madhu Babu Battu, Mallika Alvala, Dharmarajan Sriram, Perumal Yogeeswari
发表日期
2012/8/1
来源
Expert opinion on therapeutic targets
卷号
16
期号
8
页码范围
819-832
出版商
Taylor & Francis
简介
Introduction: Dysregulation of metabolic pathways, caused by imbalances in energy homeostasis, leads to type 2 diabetes characterized by high glucose concentration in the blood due to insulin resistance which is a major disorder in developed countries.
Areas covered: One of the recent treatment strategies is using activators of SIRT1, which has been in clinical trials. Many of the cellular processes including insulin secretion, cell cycle, and apoptosis are imperatively regulated by a family of mediators called sirtuins. First known mammalian sirtuin, SIRT1 is a positive regulator of insulin secretion, which triggers glucose uptake and utilization. Since the past decade, a major outstanding question is whether SIRT1 activation is a safe therapy for human diseases such as type 2 diabetes? This review summarizes and discusses the advances of the past decade and the challenges that will brazen out perplexity about …
引用总数
201320142015201620172018201920202021202220232024671333514332
学术搜索中的文章
VK Pulla, MB Battu, M Alvala, D Sriram, P Yogeeswari - Expert opinion on therapeutic targets, 2012